Novogen Patent Covering Cantrixil, Trilexium has been Granted in Australia

Novogen Limited

today announced that a patent for the superbenzopyran (SBP) family, covering the lead candidates Cantrixil and Trilexium, has been granted in Australia. This patent provides full protection of Novogen's intellectual property (IP) for the SBP family until 2035. In addition, the key patent application covering the first lead anti-tropomyosin (ATM) compound, Anisina, has been examined and accepted by the Australian Patent Office. The application has now entered the standard three-month opposition window prior to being granted. According to Novogen North America CEO, Dr Andrew Heaton, these milestones help validate the Company's discovery platforms and represent critical milestones in IP protection.  "The SBP patent covers a wide range of new chemical entities, including Cantrixil and Trilexium. Critically, the patent covers composition of matter, a new abridged method of manufacture, and treatment for a wide variety of cancer types," Dr Heaton said. "Our key SBP assets are now fully covered in